Search
Press release
Health Care
May 5, 2020

Evonik announces €25m first stage of program to increase contract manufacturing of APIs and intermediates in Germany

  • Expansion of Dossenheim and Hanau sites to increase EU supply security for drug products
  • Further entrenches Evonik’s position as a top global CMO for APIs and intermediates

Evonik today announced the €25 million first stage of a long-term program to expand the capacity of its Dossenheim and Hanau facilities in Germany to support growing pharmaceutical demand for the contract manufacturing of active pharmaceutical ingredients (APIs) and advanced intermediates within Europe.

The €25 million first stage of the expansion project for Dossenheim and Hanau is scheduled to be completed by the middle of 2021, with the entire project expected to be finalized prior to 2024.

“The COVID-19 pandemic has amplified the focus of many pharmaceutical companies to have European-based manufacturing sites that can support the production of their life-saving drug products for reliable supply to regional healthcare markets,” said Thomas Riermeier, Senior Vice President of Evonik’s Health Care business line. “The expansion of our Dossenheim and Hanau sites in Germany is now underway to support customers seeking a trusted European site for the clinical and commercial production of their APIs and intermediates.”

“In addition to increasing our production capacity for APIs and advanced intermediates within Europe, the expansion of the two multi-purpose cGMP sites in Dossenheim and Hanau, Germany will widen Evonik’s ability to support highly complex customer projects”, said Dr. Andreas Meudt, Vice President of Exclusive Synthesis for the Health Care business line of Evonik.

Such complex API projects, which are often associated with oncological, anti-viral and other specialized drug products, typically require a range of advanced technologies including continuous processing, highly pure PEGs and mPEGs, catalysis and cryogenic chemistry.

Evonik is one of the world’s leading CMOs for APIs and intermediates, and the largest manufacturer of high potency APIs (HPAPIs). It has established a broad portfolio of advanced technologies across its network of CMO sites in the United States, Germany, France, Slovakia and China.

Health Care is a key growth engine for Evonik, and part of its Nutrition & Care segment. Evonik Health Care is a globally recognized development partner and solutions provider to pharmaceutical, nutraceutical and medical device companies. Within the pharmaceutical market, it provides customers with a broad, flexible portfolio of products, technologies and services to help them reduce regulatory risk, accelerate time to market, improve supply security and generate powerful brand differentiation for their drug products.

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €13.1 billion and an operating profit (adjusted EBITDA) of €2.15 billion in 2019. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 32,000 employees work together for a common purpose: We want to improve life, day by day.

About Nutrition & Care

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,200 employees, and generated sales of around €4.6 billion in 2019.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.